Table 2 Responses details, stratification by BM response
Characteristics | All patients, n = 58 | BM-NR, n = 29 | BM-PR, n = 16 | BM-CR, n = 13 |
|---|---|---|---|---|
Initial HR, no. (%) | 54 (93) | 26 (90) | 15 (94) | 13 (100) |
Last HR, no (% of initial HR) | 22 (41) | 7 (27) | 5 (33) | 9 (69) |
Duration of HR, months (range) | 90 (10–101) | 50 (10–98) | 69 (17–96) | 87 (59–101)* |
Initial MR, no. (% of JAK2+), type | 33/44 (75) 9 CMR, 20 PMR, 4 mMR | 15 (68) 2 CMR, 11 PMR, 2 mMR | 8 (89) 6 PMR, 2 mMR | 10 (91) 7 CMR*, 3 PMR |
Last MR, no (% of initial overall MR), type | 22 (67) 9 CMR; 4 PMR, 9 mMR | 7 (47)a 2 CMR, 5 mMR | 6 (75) 3 PMR, 3 mMR | 9 (90) 7 CMR, 1 PMR, 1 mMR |
Time to BM response, months (range) | 52 (12–72) | NA | 54 (12–72) | 52 (30–72)b |
BM response duration, months (range) | 36 (12–66) | NA | 36 (12–66) | 30 (24–52) |
Last BM response, no (% of initial), type | 9 BM-CR; 14 BM-PR | NA | 14 BM-PR (88) 2 BM-NR (12) | 9 BM-CR (69) 4 BM-NR (31) |
Vascular adverse event on therapy, No (%) | 6 (10) | 3 (10) | 2 (13) | 1 (8) |
MF transformation on therapy, no (%) | 4 (7) | 4 (14) | 0 | 0 |
Duration of therapy, months (range) | 80 (15–107) | 75 (25–205) | 85 (77–107) | 83 (15–101) |
Total median follow-up, months (range) | 84 (36–107) | 81 (36–105) | 94 (67–107) | 93 (83–106) |
On study at last follow-up, no (%) | 32 (55) | 10 (35) | 13 (81) | 9 (69)* |